Decent end to 2024
06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."
Pages
62
Language
English
Published on
06/02/25
You may also be interested by these reports :
30/12/25
Despite revising our estimates and target price downward, DiaSorin remains a compelling investment opportunity. This is underpinned by strong ...
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...
11/12/25
CZM reported its full-year FY2024-25 results, aligning with guidance. Sales growth was supported by contributions from both segments, though ...
09/12/25
In addition to our estimates being revised lower, we have applied a 10% discount to peer-based valuation metrics to reflect the delayed recovery in ...